Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Multivariate analysis for local control (LC) and overall survival (OS)

From: Outcomes after stereotactic body radiotherapy for lung tumors, with emphasis on comparison of primary lung cancer and metastatic lung tumors

Variables MVA for LC MVA for OS
  HR (95% CI) P value HR (95% CI) P value
Gender (female vs. male) n.s.   0.56 (0.34-0.88) 0.012*
Tumor origin (primary vs. metastatic lung tumors) 0.21 (0.09-0.47) <0.001* 0.45 (0.28-0.73) 0.001*
Tumor diameter (per 1 cm increase) 1.70 (1.17-2.45) 0.005* 1.70 (1.30-2.21) <0.001*
SUVmax (≥ 5.9 vs. < 5.9) 1.50 (0.66-3.61) 0.331 1.41 (0.81-2.48) 0.218
Prescription dose (BED10: > 105 Gy vs. ≤ 105 Gy) 0.51 (0.27-0.93) 0.029* n.s  
Date of treatment (2001–2005 vs. 2006–2011) 2.22 (1.19-4.23) 0.011* n.s  
  1. Abbreviations: MVA multivariate analysis, LC local control, OS overall survival, HR hazard ratio, CI confidence interval, SUVmax maximum standardized uptake value, BED10 biological effective dose calculated using α/β = 10; n.s. not significant. *p < 0.05.